Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying – preclinical evidence  by Werner, Ulrich
Journal of Diabetes and Its Complications 28 (2014) 110–114
Contents lists available at ScienceDirect
Journal of Diabetes and Its Complications
j ourna l homepage: WWW.JDCJOURNAL.COMEffects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric
emptying – preclinical evidence☆☆,★
Ulrich Werner ⁎
Sanoﬁ-Aventis Deutschland GmbH, Frankfurt am Main, Germany☆☆ Conﬂicts of Interest: U.W. is an employee of
the company.
★ Funding: Funding was provided by Sanoﬁ.
⁎ Corresponding author. Sanoﬁ-Aventis Deutschla
Research and Translational Medicine, Industriepark H
D-65926, Frankfurt amMain, Germany. Tel.: +49 69 305
E-mail address: ulrich.werner@sanoﬁ.com.
1056-8727 © 2014 The Authors. Published by Elsevier I
http://dx.doi.org/10.1016/j.jdiacomp.2013.06.003a b s t r a c ta r t i c l e i n f oArticle history:
Received 19 February 2013
Received in revised form 30 May 2013
Accepted 11 June 2013
Available online 28 August 2013
Keywords:
Lixisenatide
GLP-1 receptor agonists
Gastric emptying
Postprandial glucose
Type 2 diabetes mellitusIn addition to promoting glucose homeostasis, glucagon-like peptide 1 (GLP-1) has a number of extra-
pancreatic effects that regulate appetite and body weight. GLP-1 delays gastric emptying, which is vital for
postprandial glucose (PPG) control. As GLP-1 is rapidly degraded by protease dipeptidyl peptidase-4, a
number of degradation-resistant GLP-1 receptor agonists (GLP-1RAs) have been developed for the treatment
of Type 2 diabetes mellitus. These agents can be broadly categorized as being short- or long-acting, based on
their pharmacokinetic proﬁle. Short-acting agonists predominantly affect PPG and delay gastric emptying in a
sustained manner, whereas long-acting agents largely affect fasting plasma glucose and their delay in gastric
emptying appears to be subjected to tachyphylaxis. Lixisenatide is a “short-acting” once-daily prandial GLP-
1RA. This review provides an overview of the preclinical studies that are currently available and that evaluate
the efﬁcacy of lixisenatide on gastric emptying and PPG levels. The preclinical evidence outlined in this review
supports the efﬁcacy of lixisenatide in reducing PPG excursions and delaying gastric emptying. Furthermore,
in contrast to long-acting agents, the actions of lixisenatide do not appear to be subjected to tachyphylaxis.
© 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license. 1. Introduction
Glucagon-like peptide 1 (GLP-1) is an incretin hormone that is
secreted by intestinal L cells in response to food ingestion. GLP-1
regulates glucose homeostasis through a variety of mechanisms,
including stimulation of insulin secretion from pancreatic β-cells and
inhibition of glucagon secretion from pancreatic α-cells (de Heer,
Rasmussen, Coy, & Holst, 2008; Holst, 2007; Quddusi, Vahl, Hanson,
Prigeon, & D'Alessio, 2003). GLP-1 also has a number of extra-
pancreatic effects that appear to be particularly important for the
regulation of appetite and body weight. These effects include a
slowing of gastric emptying and an increase in satiety after ingestion
of food (Flint, Raben, Astrup, & Holst, 1998;Meier et al., 2003; Naslund
et al., 2004). The rate of gastric emptying has been demonstrated to be
a major determinant of postprandial glucose (PPG) excursions and, as
such, has a signiﬁcant effect on glycemic control (Gonlachanvit et al.,Sanoﬁ and holds stocks in
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nc.Open access under CC BY-NC-SA li2003). Because GLP-1 is rapidly degraded by the protease dipeptidyl
peptidase-4 and is therefore unsuitable as a therapy for Type 2
diabetes mellitus (T2DM), several degradation-resistant GLP-1 recep-
tor agonists (GLP-1RAs) have been developed.
GLP-1RAs vary in their structure and pharmacokinetic proﬁle,
which leads to differences in their duration of action, as well as in their
efﬁcacy and safety proﬁles. These agents can be categorized based on
their pharmacokinetic properties (i.e. short- and long-acting) or
based on their regimen (i.e. twice-daily, once-daily or once-weekly
dosing). Currently marketed GLP-1RAs include exenatide immediate
release (IR; exendin-4; Byetta®, Amylin Pharmaceuticals, Inc.), which
has a mean half-life of 2.4 hours and is given as a twice-daily injection
(Goke et al., 1993); liraglutide (Victoza®, Novo Nordisk), which has a
half-life of 11–15 hours and is given as a once-daily injection
(Knudsen et al., 2000); and long-acting release (LAR) exenatide
(Bydureon®, Amylin Pharmaceuticals, Inc.), which is given as a once-
weekly injection (Malone, Trautmann, Wilhelm, Taylor, & Kendall,
2009). One of the major differences between short- and long-acting
GLP-1RAs is that the former seem to have a predominant effect on
PPG, whereas the latter have a predominant effect on fasting plasma
glucose (FPG). The efﬁcacy of the different GLP-1RAs on PPG
excursions appears to be related to their differential effects on gastric
emptying, with slower gastric emptying leading to reduced PPG
excursions (Linnebjerg et al., 2008). Studies suggest that GLP-1
regulates motor activity in the antro-pyloro-duodenal region. In
healthy human subjects, postprandial administration of GLP-1cense. 
Fig. 1. Effect of lixisenatide on basal blood glucose in rats. Study in obese Zucker
Diabetic Fatty rats (n = 6–8) implanted with osmotic mini pumps for continuous
subcutaneous delivery of lixisenatide 50 μg/kg daily or saline. Obese animals were
switched to a high-fat diet (HFD) at the 5th week of treatment. Progression of diabetes
was monitored by periodical determination of blood glucose over 12 weeks. Data are
mean ± standard error of the mean (Werner, Gerlach, Hofmann, & Herling, 2006)
Figure: data on ﬁle, Sanoﬁ.
111U. Werner / Journal of Diabetes and Its Complications 28 (2014) 110–114inhibited the number and amplitude of antral and duodenal
contractions, increased pyloric tone and stimulated isolated pyloric
pressure waves (Schirra et al., 2000). Antral-duodenal contractions
have been shown to be associated with the rate of gastric emptying,
whereas pyloric tone and phasic pressure provide a breaking
mechanism to diminish gastric outﬂow (Houghton et al., 1988;
Tougas et al., 1992). Both of these effects are thought to be mediated
via stimulation of vagal afferent nerves (Imeryuz et al., 1997).
Short-acting and long-acting GLP-1 RAs do not appear to have the
same effect on the rate of gastric emptying. In a study conducted in
rats, the delay in gastric emptying induced by long-acting liraglutide
diminishedwithin 14 days, whereas the delay induced by short-acting
exenatide IR was sustained (Jelsing et al., 2012). It is likely that the
efﬁcacy differences in the slowingof gastric emptying (and thereby the
efﬁcacy in reducing PPG excursions) of short- and long-acting GLP-
1RAs is attributable to the ‘tachyphylaxis’ effect reported by Nauck et
al., and that continuous stimulation of the GLP-1 receptor, in this
example by the long-acting GLP-1RA liraglutide, leads to an attenu-
ation of any initial efﬁcacy (Nauck, Kemmeries, Holst, & Meier, 2011).
Lixisenatide is a once-daily prandial GLP-1RA for the treatment of
T2DM (Barnett, 2011). Lixisenatide is distinctive in that it is effective
given once daily, yet retains the ability to reduce PPG. In randomized,
placebo-controlled trials, the efﬁcacy and safety of lixisenatide have
been demonstrated as monotherapy (Fonseca et al., 2012), as add-on
to oral antidiabetic drugs (Ahrén, Dimas, Miossec, Saubadu, &
Aronson, 2013; Bolli et al., 2011; Pinget et al., 2013; Ratner et al.,
2011) and in combination with basal insulin (Riddle et al., 2013a;
Riddle et al., 2013b; Seino, Min, Niemoeller, Takami, & Investigators,
2012). In this review, we focus on the efﬁcacy of lixisenatide in terms
of its efﬁcacy on PPG and related gastric emptying effects, and
examine the preclinical evidence that is currently available.
2. Lixisenatide mechanism of action
Lixisenatide is given as a once-daily 20 μg subcutaneous injection
and has a half-life of 2.8 hours (Distiller & Ruus, 2008). Lixisenatide
has a strong binding afﬁnity for the GLP-1 receptor, with approxi-
mately fourfold greater afﬁnity than native GLP-1, and 2.5- and 12.5-
fold greater afﬁnity than exenatide and liraglutide, respectively
(Thorkildsen, Neve, Larsen, Meier, & Petersen, 2003).
3. Effects of lixisenatide on postprandial glucose and gastric
emptying – clinical evidence
Several Phase II and Phase III clinical studies in patients with T2DM
have demonstrated the signiﬁcant efﬁcacy of lixisenatide versus
placebo in reducing glycated hemoglobin (HbA1c); there is particular
efﬁcacy of this agent on PPG excursions (Ahrén et al., 2013; Bolli et al.,
2011; Fonseca et al., 2012; Pinget et al., 2013; Ratner et al., 2011;
Riddle et al., 2013b; Rosenstock et al., 2013; Seino et al., 2012). As
monotherapy, for example, lixisenatide resulted in a 75% reduction in
PPG excursions versus placebo and signiﬁcant reductions in HbA1c
(Fonseca et al., 2012). Data from these studies have been reviewed in
detail elsewhere (Horowitz, Rayner, & Jones, 2013; Raccah, 2013).
One head-to-head study has compared two once-daily GLP-1RAs,
lixisenatide and liraglutide, and elucidated the potential role of
pharmacokinetic differences in PPG control (Kapitza et al., 2013). In
this 4-week, randomized study in 148 patients with T2DM inade-
quately controlled onmetformin, lixisenatide 20 μg reduced PPG after
a standardized breakfast to a signiﬁcantly greater extent than
liraglutide 1.8 mg once daily, with an estimated treatment difference
of −45.5 mg/dL, p b 0.0001 (Kapitza et al., 2013). Further investiga-
tion into the efﬁcacy of lixisenatide and the relationship between its
effects on PPG and gastric emptying have been investigated recently in
a randomized, double-blind, placebo-controlled, 4-week trial in
patients with T2DM. This study demonstrated that the reduction inPPG observed with lixisenatide is accompanied by a substantial
slowing of gastric emptying. Lixisenatide 20 μg once daily for
4 weeks signiﬁcantly reduced PPG after breakfast, lunch and dinner
compared with placebo, and these reductions were accompanied by a
signiﬁcant slowing in gastric emptying of breakfast, as assessed by 13C-
octanoic acid breath test (mean change from baseline in gastric
emptying half-life: 212 ± 279 minutes for lixisenatide versus
−24 ± 133 minutes for placebo, p = 0.0031) (Lorenz et al., 2013).
4. Efﬁcacy of lixisenatide on gastric emptying – preclinical studies
Several studies conducted in in vivo animal models have
investigated the effects of lixisenatide on both PPG and gastric
emptying.
4.1. Lixisenatide decreased postprandial glucose and reduced HbA1c in a
rat diabetes model
Initial indications of the efﬁcacy of lixisenatide on PPG excursions
came from studies in obese Zucker Diabetic Fatty (ZDF) rats, in which
single subcutaneous injections of lixisenatide at 1, 5 and 10 μg/kg
decreased plasma glucose levels (area under the curve) following an
acute oral glucose load (2 g/kg) by 41%, 70% and 81%, respectively, of
those observed in saline-treated lean control animals. Further
investigations using constant subcutaneous delivery of lixisenatide
in pre-diabetic obese ZDF rats showed that lixisenatide 50 μg/kg daily
reduced basal blood glucose (Fig. 1), resulting in an HbA1c reduction of
1.7% versus obese saline-treated controls (Werner et al., 2006).
4.2. Lixisenatide reduced postprandial glucose and slowed gastric
emptying in normoglycemic dogs
Subsequent studies in normoglycemic dogs conﬁrmed that lixisena-
tide reduces plasma glucose excursions following an oral glucose load
and that this effect is accompanied by a slowing of gastric emptying. In
this study, dogswere injectedwith lixisenatide 0.15–5 μg/kg or placebo
30 minutes prior to an oral glucose load. Lixisenatide reduced
maximum blood glucose excursions by 49–73% versus placebo
(p b 0.05) (Fig. 2A). Administration of lixisenatide at 5 μg/kg without
oral glucose load had no hypoglycemic effect and did not induce an
increase in plasma insulin. Co-administration of paracetamol with the
glucose load resulted in signiﬁcantly reduced absorption of paracetamol
in the lixisenatide-treated animals compared with controls (p b 0.05),.
Fig. 2. Effect of lixisenatide and placebo on (A) postprandial glucose excursion;
(B) gastric empting. Male fasted Beagle dogs (n = 6; body weight approximately 15 kg)
were exposed to an acute oral glucose test (2 g glucose/kg) 30 minutes after
subcutaneous doses of lixisenatide 0.15–5 μg/kg. Gastric emptying was assessed
using paracetamol dissolved in an oral glucose solution. Data are mean ± standard
error of the mean (Werner, Gerlach, Hofmann, & Herling, 2007). *p b 0.05 vs placebo.
Figure: data on ﬁle, Sanoﬁ.
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emptying (Fig. 2B) (Werner et al., 2007).
These results were conﬁrmed in a second study conducted in
normoglycemic dogs. Animals received a single subcutaneous injec-Fig. 3. Effect of lixisenatide, liraglutide and placebo on postprandial glucose in dogs.
Normoglycemic Beagle dogs (n = 6 per group) were randomly assigned to lixisenatide
1 μg/kg or liraglutide 50 or 100 μg/kg, or placebo 10 μg/kg 30 minutes prior to an oral
glucose challenge 2 μg/kg (5 mL/kg as a 40% aqueous solution). Blood sampling was
performed by puncture of the jugular vein (Werner et al., 2011). Data are mean ±
standard error of the mean (SEM). Figure: data on ﬁle, Sanoﬁ.tion of lixisenatide 1.5 μg/kg or placebo 30 minutes prior to a mixed
meal (93.4 kJ/kg energy, 19% protein, 71% carbohydrate, 10% lipid). In
the lixisenatide-treated dogs, postprandial blood glucose (PBG)
excursions were reduced by 67% compared with placebo (p b 0.05).
Reductions in PBG occurred despite signiﬁcant reductions in insulin
excursions. Lixisenatide also tended to reduce net intestinal glucose
uptake during the ﬁrst 360 minutes following the meal and reduced
plasma paracetamol by 53% versus placebo (p b 0.05), suggesting a
slowing of gastric emptying (Moore, Werner, Smith, Rodewald, &
Cherrington, 2007; Werner, Haschke, Herling, & Kramer, 2010).
4.3. Lixisenatide had a stronger postprandial effect than liraglutide in a
variety of animal models
The efﬁcacy of lixisenatide in reducing PBG excursions and its
effect on gastric emptying versus liraglutide has been investigated in a
series of in vivo studies (Werner, Kuhlmann-Gottke, Ruetten, Schäfer,
& Herling, 2011).
The efﬁcacy of lixisenatide versus liraglutide and placebo on PBG
excursions has been investigated in both normoglycemic dogs and
obese diabetic mice. In normoglycemic dogs randomly assigned to
lixisenatide 1 μg/kg or liraglutide 50 or 100 μg/kg, or placebo
30 minutes prior to an oral glucose challenge, lixisenatide 1 μg/kg
signiﬁcantly reduced PBG versus placebo at all time-points, measured
from the time of the glucose challenge to 1.5 hours post-challenge
(p b 0.05), and versus both doses of liraglutide at 30 minutes post-
challenge (p b 0.05) (Fig. 3). Post-challenge serum insulin, glucagon
levels and C-peptide were similar for lixisenatide and liraglutide
(Werner et al., 2011). In obese diabetic mice randomly assigned to
lixisenatide 10 μg/kg, liraglutide 100 or 200 μg/kg, or placebo
120 minutes prior to an oral meal challenge containing 2 g glucose
and 0.5 g lipids, lixisenatide and liraglutide both signiﬁcantly reduced
2-hour PBG versus placebo (p b 0.05) and lixisenatide 10 μg/kgwas at
least as effective as liraglutide at the 200 μg/kg dose (Werner et al.,
2011) (data on ﬁle, Sanoﬁ).
The effects on gastric emptying were evaluated in two separate
experiments in Wistar rats: one in which they received lixisenatide atFig. 4. Effect of lixisenatide and liraglutide on gastric emptying in Wistar rats. Two
separate experiments were conducted. In the ﬁrst experiment, rats (n = 8 per group)
were assigned to lixisenatide 1, 3 or 10 μg/kg or placebo; in the second experiment,
animals (n = 8 per group) were assigned to liraglutide 100, 500 or 1000 μg/kg. Gastric
emptying was assessed using the modiﬁed phenol red (PR) method 1 (0.05% PR
solution [in 1.5% HEC], 1.5 mL per rat) administered 30 minutes post-treatment. PR
content was measured photometrically at 560 nm on the removed and homogenized
stomach (Werner et al., 2011). Data are mean ± standard error of the mean (SEM).
Figure: data on ﬁle, Sanoﬁ.
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test, and another in which they received liraglutide at 100, 500 or
1000 μg/kg or placebo. Lixisenatide produced a strong and dose-
dependent decrease in the rate of gastric emptying at all doses
evaluated. Liraglutide demonstrated an effect on gastric emptying at
500 and 1000 μg/kg but had no effect at the 100 μg/kg dose (Fig. 4)
(Werner et al., 2011) (data on ﬁle, Sanoﬁ).
5. Conclusions
One of the most interesting features of GLP-1 to emerge in recent
years is its effect on the rate of gastric emptying and its relationship
with PPG excursions. In healthy volunteers and in patients with
T2DM, suppression of GLP-1-induced slowing of gastric emptying
attenuates the glucose-lowering effects of GLP-1 (Gonlachanvit et al.,
2003; Meier, Kemmeries, Holst, & Nauck, 2005), which highlights the
fundamental role of gastric emptying in PPG control. It now also
appears that continuous stimulation of the GLP-1 receptor can
attenuate this effect via tachyphylaxis at the level of the vagal nerve
and that intermittent activation is required for full efﬁcacy. In line
with this, clinical studies of GLP-1RAs have shown greater reductions
in PPG excursions for the shorter-acting versus the longer-acting
agents. In a comparison between long-acting liraglutide and short-
acting exenatide IR in patients with T2DM, exenatide had a
signiﬁcantly greater effect on PPG excursions than liraglutide (Buse
et al., 2009) and, in a direct comparison between lixisenatide and
liraglutide, lixisenatide reduced PPG after a standardized breakfast to
a signiﬁcantly greater extent than liraglutide (Kapitza et al., 2013).
These differences are thought to be due, at least in part, to a sustained
slowing of gastric emptying brought about by the shorter-acting
agents, whereas continuous receptor stimulation by the longer-acting
agents is subject to attenuation. No data are available on the efﬁcacy of
lixisenatide versus exenatide in reducing PPG excursions, although in
a head-to-head non-inferiority study of HbA1c reduction (based on a
predeﬁned non-inferiority margin of 0.4%), lixisenatide achieved its
endpoint of non-inferiority versus exenatide and also demonstrated a
better gastrointestinal tolerability proﬁle and fewer instances of
symptomatic hypoglycemia (Rosenstock et al., 2013). The most
common adverse effect relating to GLP-1RAs is nausea, which usually
diminishes with time andmay be related to ﬂuctuations in the Cmax of
the drug. Exenatide IR appears to result in a higher incidence of
nausea than both liraglutide and lixisenatide (Buse et al., 2009;
Rosenstock et al., 2013). There is no evidence of a direct relationship
between nausea and the slowing of gastric emptying associated with
GLP-1 RAs. However, gastrointestinal effects of GLP-1 RAs may be
related to their effect on gastric volume and tone (gastric accommo-
dation), which when impaired can lead to gastrointestinal symptoms
(Schirra et al., 1997). Further evidence for this relationship is provided
by reports that some patients with functional dyspepsia demonstrate
impaired accommodation of the proximal stomach (Gilja, Hausken,
Wilhelmsen, & Berstad, 1996). With all GLP-1RAs, however, nausea
and vomiting are transient, whereas the effects on gastric emptying
persist with short-acting exenatide IR and lixisenatide but not with
long-acting liraglutide and exenatide LAR.
The preclinical evidence reviewed here support the clinical
observations of the strong efﬁcacy of lixisenatide in regulating PBG
excursions and delaying gastric emptying. Signiﬁcant reductions in
PBG were demonstrated with lixisenatide in a variety of animal
models. These reductions appear to occur despite a reduction in
plasma insulin, suggesting that slowing of gastric emptying is the
primary property of GLP-1 in this situation. In our evaluation versus
liraglutide, lixisenatide demonstrated stronger efﬁcacy in reducing
PBG. Parallel studies looking at the effect on gastric emptying have
demonstrated a strong slowing effect on gastric emptying at all doses
studied. In our results, liraglutide at the 500 and 1000 μg/kg doses did
demonstrate a slowing effect on gastric emptying; however, it is likelythat this effect will have been attenuated with time. In a recent study
comparing exenatide IR to liraglutide, the delay of gastric emptying
induced by liraglutide diminished within 14 days, whereas that
induced by exenatide was sustained (Jelsing et al., 2012).
The preclinical studies reviewed here demonstrate the substantial
effect of lixisenatide on PBG excursions, which, from our evidence and
that of the other clinical and preclinical studies discussed here,
strongly suggest that this efﬁcacy is at least partly related to a slowing
effect on gastric emptying. Further studies deﬁning the precise
relationship between PBG excursions and gastric emptying are
awaited with interest.
The different properties of the GLP-1RAs are an important
consideration when choosing a therapy for patients with T2DM.
Review of GLP-1 RA safety is beyond the scope of this paper. However,
to date, GLP-1 RAs have all reported good safety proﬁles, with a low
risk for hypoglycemia (Aroda & Ratner, 2011). In terms of efﬁcacy, in
patients with relatively rapid gastric emptying, and in those who
require more effective control of PPG excursions to achieve their
glycemic targets, lixisenatide is more likely to be the appropriate
choice compared with other compounds that predominantly have an
effect on FPG. Additionally, because lixisenatide is administered once
daily, it may be a more convenient option, for many patients, than
other GLP-1RAs with more frequent dosing.
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